MBRX

Moleculin Biotech, Inc. (NASDAQ:MBRX) is a clinical-stage pharmaceutical company founded in 2015 and headquartered in Houston, Texas. The company went public in June 2016 and focuses on developing innovative drug candidates specifically designed to treat highly resistant tumors and viruses. Moleculin operates in the biotechnology sector within the broader healthcare industry, positioning itself as a specialized developer of oncology therapeutics with a particular emphasis on addressing unmet medical needs in cancer treatment where existing therapies have failed or proven inadequate.